Curis Inc (NAS:CRIS)
$ 3.96 -0.18 (-4.35%) Market Cap: 35.05 Mil Enterprise Value: 15.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

Curis Inc at Cowen Health Care Conference Transcript

Mar 13, 2019 / 03:20PM GMT
Release Date Price: $25.8 (+14.16%)
CJ Zopf
Cowen and Company - Analyst

Good morning. I am CJ Zopf, a member of the biotech equity research team here at Cowen. I'm very pleased to introduce our next presenting company, Curis. Over the past year we've seen a shift in sentiment from the excitement around the all-encompassing possibilities of immuno-oncology to a more sober view that targeted agents with clearly defined patient populations offer a straightforward path to building value.

So Curis has taken several approaches to targeted therapies in selected populations, both for heme malignancies and solid tumors, which does also include their rare breed oral checkpoint inhibitor, which happens also to be a bispecific and thus maintains that selective population appeal. So here to present an update on the Company, I'm pleased to introduce James Dentzer, President and CEO of Curis.

James Dentzer
Curis, Inc. - President & CEO

Thank you very much. Welcome to the conference. I'm on slide 2 of the corporate presentation; obviously forward-looking statements. Everything we say here is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot